Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Operations (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash from Operations for 16 consecutive years, with 4637000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 193.11% to 4637000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11188000.0 through Dec 2025, up 107.07% year-over-year, with the annual reading at 11188000.0 for FY2025, 107.07% up from the prior year.
  • Cash from Operations for Q4 2025 was 4637000.0 at Anika Therapeutics, down from 6870000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 6870000.0 in Q3 2025, with the low at 8293000.0 in Q2 2023.
  • Average Cash from Operations over 5 years is 1380450.0, with a median of 1822000.0 recorded in 2021.
  • Peak annual rise in Cash from Operations hit 656.34% in 2023, while the deepest fall reached 368.56% in 2023.
  • Over 5 years, Cash from Operations stood at 4472000.0 in 2021, then tumbled by 89.24% to 481000.0 in 2022, then surged by 656.34% to 3638000.0 in 2023, then plummeted by 56.51% to 1582000.0 in 2024, then surged by 193.11% to 4637000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 4637000.0, 6870000.0, and 189000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.